Generate:Biomedicines vs Isomorphic Labs
The two most talked about generative protein companies, and the quieter one has gone considerably further. Generate designs protein therapeutics de novo, with a public listing that forced detailed disclosure of the platform, the pipeline and the economics, the strongest transparency posture in this category, and clinical stage assets behind it. Isomorphic has the more celebrated lineage, descending from the structure prediction work that changed the field, and a unified design engine spanning structure, binding, affinity and antibody modelling, with named pharmaceutical collaborations. It also has no software to license, no published method behind the commercial engine and no molecule in a human being yet. Pedigree against pipeline, and for a partner deciding where to place a programme, the pipeline is the evidence.
- The model generates novel protein structures and sequences rather than filtering natural scaffolds, so the design is the origin of the molecule rather than a screen applied to it.
- The regulatory and clinical position is the most advanced in this category alongside one peer, with a public listing forcing detailed disclosure of the platform and pipeline.
- Transparency is the strongest in this category, which is a direct counterexample to the closed posture common among well funded discovery companies.
- The lineage is the strongest in structure prediction and the engine unifies structure, ligand binding, affinity and antibody interaction modelling in one system.
- Named multi target discovery collaborations tell a partner what working with the company actually involves.
- Designs enter a pharmaceutical partner's own development process, so the oversight is structurally the partner's rather than internal.
Side by Side
| Axis | G Generate:Biomedicines |
I Isomorphic Labs |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
The disclosure asymmetry is the story here. One company is publicly listed with a filed registration statement describing the platform, the pipeline and the economics, and no molecule from the other has entered a human, with first in human work targeted for the end of 2026 and no published method or benchmark behind the commercial engine. Neither publishes a security attestation.
For protein design specifically, the governance question is biosecurity rather than bias, and neither publishes a release policy or an intended use statement for models capable of generating novel functional proteins.